论文部分内容阅读
在考察先进国家经验和我国医药产业发展现状的基础上,指出在加入WTO前提下,我国医药产业发展所面临的“双重困境”。文章重点分析了近年来跨国制药巨头在华扩张从销售、生产逐步延伸到临床试验和研发环节的趋势,及其通过正式或非正式手段对我国医药公共科研基础、临床试验资源的渗透与利用。揭示了这一“困境”中所存在的机遇,探讨了中国制药企业走出困境的战略选择。
On the basis of examining the experiences of advanced countries and the status quo of the development of China’s pharmaceutical industry, we point out the “dual dilemmas” faced by the development of China’s pharmaceutical industry under the precondition of joining the WTO. This article focuses on the trend of the expansion of multinational pharmaceutical giants in China from sales and production to clinical trials and research and development in recent years. It also penetrates and utilizes public medical research bases and clinical trial resources in China through formal or informal means. It reveals the opportunities that exist in this “dilemma” and discusses the strategic choices for China’s pharmaceutical companies to emerge from the predicament.